Poor adherence to highly active antiretroviral therapy and associated factors among people living with HIV in Eastern Ethiopia.
Eastern Ethiopia
Harar
Poor adherence
anxiety
depression
highly active antiretroviral therapy
Journal
SAGE open medicine
ISSN: 2050-3121
Titre abrégé: SAGE Open Med
Pays: England
ID NLM: 101624744
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
10
2021
accepted:
10
05
2022
entrez:
30
6
2022
pubmed:
1
7
2022
medline:
1
7
2022
Statut:
epublish
Résumé
Sustained adherence to highly active antiretroviral therapy is necessary to suppress viral replication and improve immunological and clinical outcomes. Although different studies tried to identify factors affecting adherence to highly active antiretroviral therapy, there are few studies after initiation of test and start strategy and the first-line drug regimen change in the study area. Therefore, this study aimed to determine the level of adherence to highly active antiretroviral therapy and associated factors among people living with HIV in Eastern Ethiopia. Institutional-based cross-sectional study design was conducted from 2 March 2020, to 30 March 2020. A total of 501 study participants were recruited using systematic random sampling. Data were collected using face-to-face interviews at the end of the clinic visit and a review of participants' medical records. The level of adherence to highly active antiretroviral therapy was measured using the eight-item Morisky Medication Adherence Scale. The score ranges from 0 to 8, and a score of less than 8 indicates poor adherence. The data were entered into EpiData and exported to STATA for further analysis. The binary logistic regression analysis model was employed to identify associated factors. The association was reported with an adjusted odds ratio and a 95% confidence level. The significance level was declared at p = 0.05. A total of 501 participants participated in the study, giving a response rate of 98.2%. The majority (314 or 62.7%) of study participants were females. The participants' mean (standard deviation) age was 38.17 (8.75). The level of poor adherence to highly active antiretroviral therapy was found to be 33.73% (confidence interval: 29.70, 38.00). Age category 35 to 44 (1.65 (confidence interval: 1.02, 2.69)), no shortage of highly active antiretroviral therapy (0.46 (confidence interval: 0.28, 0.75)), substance use (1.67 (confidence interval: 1.11, 2.25)), having moderate depressive symptoms (4.00 (confidence interval: 1.94, 8.48)), and moderate anxiety symptoms (5.22 (confidence interval: 2.31, 8.84)) were significantly associated with the poor adherence to highly active antiretroviral therapy among adult people living with HIV. The level of poor adherence to highly active antiretroviral therapy was found to be high in this study. Poor adherence to highly active antiretroviral therapy was significantly associated with age, availability of highly active antiretroviral therapy drugs, substance usage, depressive symptoms, and anxiety symptoms. Improving the adherence levels requires stringent counseling, assuring continuous drug availability, and timely screening and management of depression and anxiety.
Identifiants
pubmed: 35769492
doi: 10.1177/20503121221104429
pii: 10.1177_20503121221104429
pmc: PMC9234842
doi:
Types de publication
Journal Article
Langues
eng
Pagination
20503121221104429Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Public Health Rep. 2012 Jan-Feb;127(1):2-3
pubmed: 22298918
BMC Public Health. 2014 Dec 19;14:1308
pubmed: 25526773
AIDS Behav. 2010 Apr;14(2):289-99
pubmed: 18648925
AIDS. 2014 Aug 24;28(13):1945-56
pubmed: 24845154
Pan Afr Med J. 2019 Jul 31;33:277
pubmed: 31692880
J Int Assoc Provid AIDS Care. 2014 Jul-Aug;13(4):346-52
pubmed: 25513032
BMC Int Health Hum Rights. 2015 Dec 28;15:33
pubmed: 26711659
Acad Emerg Med. 2011 Oct;18(10):1099-104
pubmed: 21996075
Rev Chilena Infectol. 2014 Jun;31(3):323-8
pubmed: 25146207
AIDS Care. 2010 Mar;22(3):381-9
pubmed: 20390519
PLoS One. 2021 Sep 2;16(9):e0256948
pubmed: 34473774
AIDS. 2017 Jan 28;31(3):401-406
pubmed: 27677168
Front Pharmacol. 2017 Nov 23;8:831
pubmed: 29218008
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
BMC Psychol. 2018 Jul 17;6(1):31
pubmed: 30016997
HIV AIDS (Auckl). 2021 Dec 15;13:1067-1078
pubmed: 34955657
Ethiop J Health Sci. 2019 May;29(3):299-308
pubmed: 31447498
AIDS. 2007 Aug 20;21(13):1799-803
pubmed: 17690579
J Affect Disord. 2004 Jul;81(1):61-6
pubmed: 15183601
PLoS Med. 2009 Apr 28;6(4):e1000056
pubmed: 19399154
BMC Public Health. 2014 Apr 15;14:365
pubmed: 24735561
J Antimicrob Chemother. 2010 Jul;65(7):1505-9
pubmed: 20498120
AIDS Educ Prev. 2009 Jun;21(3 Suppl):94-105
pubmed: 19537957
J Prim Care Community Health. 2020 Jan-Dec;11:2150132720902561
pubmed: 32321354
J Clin Hypertens (Greenwich). 2008 May;10(5):348-54
pubmed: 18453793
Ann Intern Med. 2000 Jul 4;133(1):21-30
pubmed: 10877736
BMC Public Health. 2020 Nov 26;20(1):1802
pubmed: 33243185
Curr HIV/AIDS Rep. 2014 Sep;11(3):291-307
pubmed: 25038748
Cad Saude Publica. 2015 Jun;31(6):1188-98
pubmed: 26200367
AIDS. 2003 Jun 13;17(9):1369-75
pubmed: 12799558
Health Policy Plan. 2009 May;24(3):189-96
pubmed: 19276155
HIV AIDS (Auckl). 2021 May 25;13:581-592
pubmed: 34079385
HIV AIDS (Auckl). 2020 Mar 09;12:97-106
pubmed: 32210636